WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney’s commercial strategy as the Company advances towards the potential commercialization of rilparencel. “Greg is a seasoned commercial biopharma executive with a proven track reco ...

Exhibit 99.1 ProKidney Reports Full Year 2025 Financial Results and Business Highlights WINSTON-SALEM, N.C., March 18, 2026 – ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the full year ended December 31, 2025, and provided business highlights. "2025 was a pivotal year for ProKidney, highlighted by positive Phase 2 REGEN-007 study results, alignment with the FDA o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40560 ProKidney Corp. (Exact name of Registrant as specified in its Charter) Delaware 98-1586514 (State or other jurisdiction of inco ...

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 millio ...

Core Insights - Inter & Co, Inc. (NASDAQ:INTR) operates in the financial services sector, facing competition from various financial service providers such as Alvotech, ProKidney Corp., Global Business Travel Group, Inc., and Commercial International Bank (Egypt) S.A.E. [1] Financial Performance - Inter & Co, Inc. has a Return on Invested Capital (ROIC) of 1.42% and a Weighted Average Cost of Capital (WACC) of 10.00%, resulting in a ROIC to WACC ratio of 0.14, indicating potential inefficiencies in capital utilization [2][6] - Alvotech (ALVO) has a ROIC of 3.74% and a WACC of 7.98%, leading to a ROIC to WACC ratio of 0.47, suggesting more effective capital utilization compared to INTR [3] - Global Business Travel Group, Inc. (GBTG) shows a ROIC of 3.59% and a WACC of 8.57%, with a ROIC to WACC ratio of 0.42, indicating better capital efficiency than INTR [3] - ProKidney Corp. (PROK) has a negative ROIC of -52.92% and a WACC of 12.14%, resulting in a ROIC to WACC ratio of -4.36, highlighting significant challenges in capital utilization [4] - Commercial International Bank (Egypt) S.A.E (CIBEY) stands out with a ROIC of 28.66% and a WACC of 22.91%, achieving a ROIC to WACC ratio of 1.25, indicating efficient capital utilization and potential for higher shareholder value [5][6]

Core Viewpoint - The article does not provide any specific insights or analysis related to companies or industries, focusing instead on the author's qualifications and disclosures [1][2][3]. Group 1 - The author holds multiple degrees in Electronics and Telecommunication Engineering, Computer Science, Business Management, and Computer Applications from various institutions [1]. - The author collaborates professionally with another individual, ensuring that analyses are conducted independently [1]. - There is a clear disclosure regarding the lack of stock or derivative positions in any mentioned companies, indicating no potential conflicts of interest [2]. Group 2 - The article emphasizes that past performance does not guarantee future results, highlighting the importance of independent analysis [3]. - It clarifies that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article notes that the analysts may not be licensed or certified, which could impact the credibility of the analyses presented [3].

Company Overview - ProKidney aims to transform the treatment landscape for patients with advanced chronic kidney disease, particularly those at high risk of kidney failure and potential dialysis [2][4] - The company's lead product, rilparencel, is positioned as a meaningful intervention to alter the progression of kidney disease towards failure [3] Market Context - There are over 3 million Americans currently suffering from advanced chronic kidney disease, with many facing a high risk of developing kidney failure in the coming years [4] - The majority of these patients will require dialysis, while a fortunate few may receive kidney transplants, highlighting the urgent need for effective treatment options [4]

ProKidney Conference Call Summary Company Overview - **Company**: ProKidney - **Industry**: Healthcare, specifically focused on chronic kidney disease (CKD) treatment - **Product**: Rilparencel, an autologous cell therapy aimed at treating advanced chronic kidney disease Key Points and Arguments Market Opportunity - Over 3 million Americans suffer from advanced chronic kidney disease, with many at high risk of kidney failure and requiring dialysis [2][4] - Rilparencel aims to provide a transformative treatment option for these patients, allowing them more time and flexibility in their lives [3] Product Development - Rilparencel has shown kidney function stabilization in multiple phase two trials, with over 150 patients treated [3] - The therapy has a favorable safety profile, requiring no preconditioning or immunosuppression [3][6] - A pivotal phase three study (PROACT 1) is ongoing, with a readout expected in Q2 2027 [5][19] Regulatory Progress - ProKidney has aligned with the FDA on an accelerated approval pathway using eGFR slope as a surrogate endpoint [4][17] - The company is actively engaging with the FDA under the RMAT designation [5] Manufacturing and Capacity - ProKidney is expanding its in-house manufacturing facilities in Winston-Salem, North Carolina, to support clinical and commercial needs [5][9] - The manufacturing process involves harvesting kidney cells from patients, expanding them, and then cryopreserving the product for injection [7][8] Clinical Study Insights - The phase three study design is robust, randomized, and sham-controlled, focusing on patients with type 2 diabetes and advanced CKD [17] - Enrollment is progressing well, with expectations to complete enrollment for the accelerated approval cohort by mid-2026 [29] Financial Position - As of September, ProKidney had $270 million in cash, sufficient to fund operations into mid-2027 [28] Efficacy and Safety Data - In a phase 2 study, the annual decline in eGFR slope improved by 78% after treatment with rilparencel [25][26] - No serious adverse events related to rilparencel were reported, indicating a consistent safety profile [26][27] Future Plans - ProKidney plans to continue R&D efforts to elucidate the mechanism of action for rilparencel, with data expected throughout 2026 [20][34] - Preparations for a Biologics License Application (BLA) submission and commercial launch are underway [39] Additional Important Content - The company recognizes the need for better representation of underrepresented patient groups in clinical trials and is actively working to address this in the phase three program [24][25] - The mechanism of action for rilparencel is believed to involve anti-inflammatory effects and the utilization of innate restorative mechanisms in the kidney [33] This summary encapsulates the critical insights and developments discussed during the ProKidney conference call, highlighting the company's strategic direction and the potential impact of its lead product on the treatment of advanced chronic kidney disease.

NASDAQ PROK Transforming the Future of Chronic Kidney Disease Treatment Preserving Kidney Function in Patients at High Risk of Kidney Failure 44th Annual J.P. Morgan Healthcare Conference Bruce Culleton, MD Chief Executive Officer January 14, 2026 Copyright © 2026 ProKidney Corp. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual ...

Group 1 - ProKidney Corp. is a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD) [1] - The CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [2] - ProKidney's lead product candidate, rilparencel (REACT), is a first-in-class autologous cell therapy aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes [3] Group 2 - The ongoing Phase 3 REGEN-006 (PROACT 1) study is evaluating the potential of rilparencel to improve kidney function [3] - ProKidney was founded in 2015 after a decade of research in cell therapy for CKD [3] - The live webcast of the presentation will be accessible through ProKidney's website, with a replay available for 30 days post-event [2]